Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single and multiple ascending dose study of KP-910 in healthy adult and elderly males
jRCT2071230041Phase 1Completed
- Sponsor
- Kaken Pharmaceutical Co., Ltd.
- Start
- Aug 2023
- Countries
- 1
01
Overview
Phase 1 trial of KP-910 (2 arms), sponsored by Kaken Pharmaceutical Co., Ltd. Primary endpoints: Safety and tolerability of KP-910 and Pharmacokinetics of KP-910. Started Aug 2023; status: completed.
02
Drugs
KP-910
Beyond the preview
Go deeper on jRCT2071230041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230041.